1. Introduction {#sec1}
===============

Head and neck cancer (HNC) is the sixth most common cancer \[[@B1]\], which includes oral cancer, nasopharyngeal carcinoma, pharyngeal cancer and laryngeal neoplasm. Most of HNC patients are over 50-60 years old, but the number of younger patients has increased recently \[[@B2]\]. According to statistics, an estimated 650,000 new cases of HNC and 350,000 deaths occur each year worldwide \[[@B3]\]. Esophageal cancer (EC) is one of the most common carcinomas that ranks eighth in incidence rate and ranks sixth in mortality rate \[[@B4]\]. In recent decades, many studies have reported that patients with HNC were at a higher risk of developing concomitant EC than general persons, particularly cancers of the oral cavity \[[@B5]--[@B12]\]. Besides, a few papers put forward that patients with EC also have an increased risk of a second OC \[[@B13], [@B14]\]. The bidirectional association between OC and EC was well established by Chuang et al. \[[@B14]\] and Lee et al. \[[@B15]\], no matter which one occurs first.

The strong correlation between the incidence of HNC and the incidence of EC might be because these two cancers share some same factors. Although the primary risk factors for HNC and EC are smoking and heavy alcohol intake \[[@B16], [@B17]\], only a small minority of these subjects will develop HNC or EC \[[@B18]--[@B20]\], suggesting that genetic susceptibility might also be strongly associated with the development of these two cancers \[[@B20]--[@B25]\].

RAD51 gene, mapped to chromosome 15q15.1 in people, belongs to the system of DNA repair gene \[[@B26]\]. RAD51 protein encoded by the gene has a significant effect on the repairment of damaged DNA and maintaining genomic integrity \[[@B27]\]. 135 G/C (rs1801320) and 172 G/T (rs1801321) are two common RAD51 single nucleotide polymorphisms (SNPs), which might influence mRNA stability and relate to altered translational efficiency \[[@B28]\]; thus, these two gene polymorphisms might lead to carcinogenesis.

To date, a variety of articles have been conducted to assess the correlation between the RAD51 gene polymorphisms and the risk of HNC and EC \[[@B29]--[@B39]\]. However, the results are still inconsistent. For instance, Sun et al. \[[@B39]\] demonstrated G135C polymorphism in RAD51 gene was strongly related to EC, while Zhang et al. \[[@B37]\] did not discover the significant relationship between EC and polymorphisms in RAD51. So the meta-analysis was conducted to examine the correlation between the polymorphisms in RAD51 gene and the susceptibility to HNC and EC.

2. Material and Methods {#sec2}
=======================

2.1. Selection of Relevant Papers {#sec2.1}
---------------------------------

Relevant papers were searched in databases of PubMed, Web of Science, and Embase prior to August 17, 2019. Selection strategy was carried out by combination of the following terms: "RAD51", "135G/C", "rs1801320", "172G/T", "rs1801321", "polymorphism", "polymorphisms", "variant", "mutation", "SNP", "HNC", "head and neck", "oral", "oral cavity", "pharyngeal", "laryngeal", "nasopharyngeal", "oropharyngeal", "laryngopharyngeal", "hypopharyngeal", "esophageal", "oesophageal", "cancer", "carcinoma", "tumor", "tumour", "malignancy", and "neoplasm". Furthermore, references cited by all the retrieved papers were checked to identify potentially relevant articles.

2.2. Inclusion and Exclusion Criteria {#sec2.2}
-------------------------------------

Our meta-analysis was performed follow the recommendations of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement \[[@B40]\].

Papers which met all the following criteria were enrolled in the present meta-analysis: (1) associated with the correlation between the RAD51 SNP and the EC or HNC, (2) case-control studies, and (3) sufficiency of the data provided by the paper for estimating the correlation. Publications satisfying one of the following criteria were excluded: (1) unavailability of full text, (2) no sufficient information on data reported, and (3) duplicated papers, reviews, editorials, case reports, commentaries, and case-only studies.

2.3. Data Extraction and Quality Assessment {#sec2.3}
-------------------------------------------

The following information on data were fetched by two writers, respectively, from each enrolled study: name of primary author, publication year, country where paper was performed, ethnicity of the study subjects, counts of case groups and control groups, source of the control groups, genotyping methods, genotype and allele for case and control frequencies, type of tumor, and *P* value of the Hardy-Weinberg equilibrium (HWE) in controls. Cases of disagreement were resolved by two writers. Quality assessment of each paper enrolled in the analysis was performed by the Newcastle-Ottawa Scale (NOS) criteria \[[@B41]\].

2.4. False-Positive Report Probability (FPRP) Analysis {#sec2.4}
------------------------------------------------------

The significant results were also assessed by the false-positive report probability (FPRP) \[[@B42]\]. We set 0.5 as FPRP threshold and assigned a prior probability of 0.1 to detect an odds ratio (OR) of 1.50 for an association with genotypes under investigation. Only the significant finding with a FPRP value \< 0.5 was considered as a noteworthy result.

2.5. Statistical Analysis {#sec2.5}
-------------------------

STATA 11.0 (College Station, Texas 77845, United States) was used to calculate the pooled ORs along with corresponding 95% confidence intervals (95% CIs), in order to examine the correlation between RAD51 SNPs and the risk of these two cancers. The allelic, homozygous, heterozygous, dominant, and recessive genetic models were examined in our meta-analysis. Subgroup analyses based on genotyping method, ethnicity, sample size (large sample was defined by the overall number of cases and controls greater than 400; small sample was defined by the sample size equal to 400 or less than 400), and tumor type were conducted. The value of *P* \< 0.05 in *Z*-test was regarded as statistically significant.

Heterogeneity was evaluated by Cochran\'s *Q*-statistic and *I*^2^ test. If *P* value in *Q*‐test \< 0.10 or *I*^2^ \> 50%, the DerSimonian and Laird random-effects model was used to count the ORs. Otherwise, the Mantel-Haenszel fixed-effects model was conducted to assess the correlation between RAD51 SNPs and these two cancers. Sensitivity analysis was performed by deleting an article at a time in order to evaluate the reliability and stability of the pooled results. Publication bias was evaluated by Begg\'s funnel plots and Egger\'s tests. If the *P* value \< 0.05, the publication bias was considered significant.

3. Results {#sec3}
==========

3.1. Eligible Papers and Paper Characteristics {#sec3.1}
----------------------------------------------

According to the inclusion and exclusion criteria, ten papers involving a total of 2484 controls and 2377 cases were enrolled in our analysis after selection \[[@B29], [@B31]--[@B39]\]. The progress of paper selection is demonstrated in [Figure 1](#fig1){ref-type="fig"}.

All the enrolled papers were related to RAD51 G135C (rs1801320) polymorphism. Among ten articles, four were correlated with RAD51 G172T (rs1801321) polymorphism. There are seven articles for HNC and three articles for EC. Five articles were conducted in Caucasians; four articles were performed on Asians. All papers showed that the genotype distribution in the controls was consistent with HWE, except 2 papers \[[@B34], [@B39]\]. The detailed data of these enrolled articles are presented in Tables [1](#tab1){ref-type="table"} and [2](#tab2){ref-type="table"}.

3.2. Results of Meta-Analysis {#sec3.2}
-----------------------------

The correlation between the RAD51 polymorphisms and these two cancers is displayed in Tables [3](#tab3){ref-type="table"} and [4](#tab4){ref-type="table"}.

With respect to RAD51 G135C (rs1801320) polymorphism, the random-effects model was performed under all genetic models because the statistical heterogeneity between articles was substantial (value of *P* in *Q*‐test \< 0.10 or *I*^2^ \> 50%). We discovered a significant relationship between the rs1801320 polymorphism and the increased risk of these two cancers under all genetic models except homozygous and recessive models (OR = 1.32, (95%CI, *P*) = (1.03‐1.71, 0.032) for C vs. G, [Figure 2](#fig2){ref-type="fig"}; OR = 1.34, (95%CI, *P*) = (0.69‐2.61, 0.388) for CC vs. GG; OR = 1.50, (95%CI, *P*) = (1.03‐2.19, 0.033) for CG vs. GG; OR = 1.44, (95%CI, *P*) = (1.05‐1.99, 0.026) for CC+CG vs. GG; and OR = 1.15, (95%CI, *P*) = (0.57‐2.34, 0.696) for CC vs. CG+GG). In our subgroup analyses, a statistically significant correlation was observed for PCR-RFLP genotyping method subgroup (OR = 1.52, 95%CI = 1.15‐2.02 for C vs. G; OR = 1.84, 95%CI = 1.19‐2.86 for CG vs. GG; and OR = 1.74, 95%CI = 1.20‐2.51 for CC+CG vs. GG), Asians (OR = 1.89, 95%CI = 1.16‐3.08 for C vs. G; OR = 2.20, 95%CI = 1.30‐3.74 for CC vs. GG; OR = 2.06, 95%CI = 1.13‐3.76 for CG vs. GG; OR = 2.06, 95%CI = 1.17‐3.64 for CC+CG vs. GG; and OR = 1.89, 95%CI = 1.12‐3.19 for CC vs. CG+GG), large sample subgroup (OR = 1.41, 95%CI = 1.02‐1.96 for C vs. G; OR = 1.75, 95%CI = 1.01‐3.01 for CG vs. GG; and OR = 1.61, 95%CI = 1.04‐2.51 for CC+CG vs. GG), and EC (OR = 2.07, 95%CI = 1.01‐4.25 for C vs. G; OR = 2.08, 95%CI = 1.17‐3.71 for CC vs. GG; and OR = 1.78, 95%CI = 1.00‐3.15 for CC vs. CG+GG).

As for RAD51 G172T (rs1801321) polymorphism, four papers enrolled were all related to HNC instead of EC. The random-effects model was performed under all genetic models, because the statistical heterogeneity between articles was substantial (value of *P* in *Q*‐test \< 0.10 or *I*^2^ \> 50%). Significant correlation was not observed between rs1801321 polymorphism and susceptibility to HNC. In our subgroup analyses by genotyping method, ethnicity, and sample size, a significant correlation could be observed between the rs1801321 polymorphism and the decreased risk of HNC for Caucasians only (OR (95%CI) = 0.82 (0.72‐0.95) for T vs. G).

3.3. Sensitivity Analyses and Publication Bias {#sec3.3}
----------------------------------------------

Sensitivity analyses indicated that there was no substantive change in the combined ORs after excluding each article at a time ([Figure 3](#fig3){ref-type="fig"}, C vs. G of rs1801320). Publication bias was assessed by the Egger linear regression tests and Begg\'s funnel plots. In all studies, no remarkable publication bias was shown by the *P* value in the Egger test (C vs. G: *P* = 0.980; CC vs. GG: *P* = 0.299; CG vs. GG: *P* = 0.710; CC+CG vs. GG: *P* = 0.848; CC vs. CG+GG: *P* = 0.374; T vs. G: *P* = 0.540; TT vs. GG: *P* = 0.579; TG vs. GG: *P* = 0.669; TT+TG vs. GG: *P* = 0.625; TT vs. TG+GG: *P* = 0.595) and Begg\'s funnel plot ([Figure 4](#fig4){ref-type="fig"}, C vs. G of rs1801320) for rs1801320 and rs1801321 polymorphisms.

3.4. FPRP Analysis Results {#sec3.4}
--------------------------

The results of FPRP analyses for all discovered significant findings are listed in [Table 5](#tab5){ref-type="table"}. For a prior probability of 0.1, the FPRP values were most less than 0.50 in the significant findings, suggesting that the most of these significant relationships were noteworthy although the FPRP values were more than 0.50 in three subgroup analysis (C versus G: in the EC subgroup; CG versus GG: in the large sample subgroup; CC versus CG+GG: in the EC subgroup).

4. Discussion {#sec4}
=============

Reduced DNA repair capacity might lead to genomic instability and eventually result in tumorigenesis, which has aroused widespread concern. The RAD51 protein in human plays an essential role in repairing DNA breaks and maintaining the genetic steady. Two common RAD51 SNPs (rs1801320 and rs1801321) might influence mRNA stability and relate to the expression level of RAD51 protein.

In recent years, a number of papers have focused on the correlation between HNC, EC, and RAD51 gene polymorphisms. However, the observed correlations of these papers between two cancers and RAD51 SNPs were inconclusive. Therefore, we conducted a meta-analysis to assess the correlation between RAD51 SNPs and the risk of HNC and EC. Our results revealed that rs1801320 polymorphism was significantly correlated to the risk of these two cancers under the allelic, heterozygous, and dominant genetic models. Nevertheless, no association between the rs1801321 polymorphism and the development of HNC was found.

In the subgroup analyses of rs1801320 polymorphism according to a genotyping method, a statistically significant relationship was found in the PCR-RFLP genotyping method subgroup under allelic, heterozygous, and dominant genetic models, but not in the PCR genotyping method subgroup. This might be because different genotyping method would influence the association, indicating that a genotyping method with high sensitivity and specificity is required to increase the accuracy of results. In the subgroup analyses based on ethnicity, we discovered rs1801320 polymorphism increased the risk of HNC and EC in Asian populations, but not in Caucasian populations. This might be due to the following reasons. Firstly, it might be because the genetic trait was considerably different in various ethnicities. Secondly, it could be because the individuals\' genetic susceptibility and environmental factors are diverse in different ethnic groups. When stratified by sample size, the rs1801320 polymorphism was related to the increased risk of HNC and EC in a large sample subgroup under the allelic, heterozygous, and dominant genetic models, which was the same as the overall results. Nevertheless, no marked association was discovered in a small sample subgroup. This might suggest that more studies with a large sample size are required to assess the correlation between RAD51 SNPs and the susceptibility to HNC and EC. Stratified analysis according to tumor type indicated that a marked correlation could be found between rs1801320 polymorphism and EC under the allelic, homozygous, and recessive genetic models, but not found between the SNP and the HNC. This indicated that rs1801320 polymorphism would contribute to the development of EC.

In the subgroup analyses of rs1801321 polymorphism by a genotyping method and sample size, no statistical evidence of correlation was observed between rs1801321 SNP and HNC. Stratified analysis based on ethnicity, our results revealed that rs1801321 SNP was related to the decreased risk of HNC among Caucasian populations under an allelic genetic model.

To the best of our knowledge, our study is proposed as the first one to observe the correlation between the RAD51 gene polymorphisms and the susceptibility to these two associated cancers. It is particularly worth mentioning here that rs1801320 polymorphism could increase the risk of EC, which had not been shown before. A previous meta-analysis carried out by Kong et al. \[[@B30]\] was performed to assess the effect of RAD51 polymorphisms on the susceptibility to HNC. In addition, some other meta-analyses were conducted to study the correlation between RAD51 polymorphisms and cancers including HNC \[[@B43]--[@B45]\]. Comparing with them, our analysis has some differences and improvements. Firstly, no correlations were observed between RAD51 gene polymorphisms and HNC, which did not correspond with previous studies \[[@B30], [@B43], [@B44]\]. Secondly, this is the first study not only to assess the correlation between RAD51 SNPs and two associated cancers (HNC and EC) but also to discover a relationship between the rs1801320 polymorphism and the risk of EC. Thirdly, we performed an updated study with more comprehensive data. Additionally, we conducted the FPRP analysis, and the results of FPRP analysis showed that most of the significant findings in our study are robust. There is no doubt that our present results will be more reliable.

However, some limitations exited in our analysis. First, the subgroup analyses could not have sufficient statistical power to identify the association because of the limited studies. Second, some eligible studies that have not published were not included in the present analysis, so publication bias could potentially exist. Third, subgroup analyses based on gender, smoking, or alcohol consumption were not performed since relevant data could not be obtained from most of the enrolled studies. Finally, the FPRP analysis results showed that the significant relationships of three subgroup analysis were not noteworthy (C versus G: in the EC subgroup, CG versus GG: in the large sample subgroup, and CC versus CG+GG: in the EC subgroup). So further analyses are required to investigate the effects on the gene-environment interaction.

5. Conclusions {#sec5}
==============

The present meta-analysis explored that rs1801320 SNP was significantly correlated with the risk of these two associated cancers. Moreover, the correlation between the rs1801320 SNP and the susceptibility to EC was pointed out at the first time. However, more high-quality papers with a large sample size should be addressed to assess the correlation between RAD51 polymorphisms and cancer susceptibility.
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###### 

The detailed characteristics of included studies.

  First name (year)            Country    Ethnicity   Control type   Sample size cases/controls   Genotyping method   Cancer type
  ---------------------------- ---------- ----------- -------------- ---------------------------- ------------------- -------------
  Lu (2007)                    USA        Caucasian   HCC            716/719                      PCR-RFLP            HNC
  Werbrouck (2008)             Belgium    Caucasian   HCC            152/157                      PCR                 HNC
  Sliwinski (2010)             Poland     Caucasian   HCC            191/353                      PCR-RFLP            HNC
  Gresner (2012)               Poland     Caucasian   PCC            81/111                       PCR                 HNC
  Romanowicz-Makowska (2012)   Poland     Caucasian   PCC            253/253                      PCR-RFLP            HNC
  Xue-Jiao (2013)              China      Asian       HCC            123/61                       PCR-RFLP            EC
  Shu-Xiang (2014)             China      Asian       PCC            316/316                      PCR-RFLP            EC
  Kayani (2014)                Pakistan   Asian       HCC            200/150                      PCR-RFLP            HNC
  Ming-Zhong (2014)            China      Asian       HCC            219/258                      PCR-RFLP            EC
  Santos (2018)                Brazil     Unknown     HCC            126/130                      TaqMan              HNC

HCC: hospital-based case control; PCC: population-based case control; PCR: polymerase chain reaction; RFLP: restriction fragment length polymorphism.

###### 

Characteristics of included studies for RAD51 polymorphisms.

  -------- ---------------------------- ------------------ --------------------- -------------------- ----------------------- ----------- -----------
  SNP      First name (year)            Cases (GG/GC/CC)   Controls (GG/GC/CC)   Cases (G/C-allele)   Controls (G/C-allele)   *P* (HWE)   NOS score
  135G/C   Lu (2007)                    624/91/1           622/96/1              1339/93              1340/98                 0.170       7
           Werbrouck (2008)             136/15/1           134/23/0              287/17               291/23                  0.322       7
           Sliwinski (2010)             101/88/2           258/64/32             290/92               580/128                 \<0.001     8
           Gresner (2012)               67/13/1            71/14/2               147/15               156/18                  0.217       8
           Romanowicz-Makowska (2012)   174/69/10          190/58/5              417/89               438/68                  0.816       7
           Xue-Jiao (2013)              83/35/5            54/6/1                201/45               114/8                   0.123       6
           Shu-Xiang (2014)             206/100/10         216/92/8              512/120              524/108                 0.626       7
           Kayani (2014)                120/70/10          106/41/3              310/90               253/47                  0.674       7
           Ming-Zhong (2014)            144/56/19          223/24/11             344/94               470/46                  \<0.001     7
           Santos (2018)                110/16/0           111/17/2              236/16               239/21                  0.174       8
                                                                                                                                          
                                        Cases (GG/GT/TT)   Controls (GG/GT/TT)   Cases (G/T-allele)   Controls (G/T-allele)               
  172G/T   Lu (2007)                    261/351/104        240/335/144           873/559              815/623                 0.169       7
           Gresner (2012)               36/43/2            43/54/13              115/47               140/80                  0.524       8
           Kayani (2014)                83/90/27           99/49/2               256/144              247/53                  0.132       7
           Santos (2018)                51/52/23           51/56/23              154/98               158/102                 0.271       8
  -------- ---------------------------- ------------------ --------------------- -------------------- ----------------------- ----------- -----------

###### 

Results of overall and subgroup analyses for rs1801320.

                 No   C versus G   CC versus GG   CG versus GG   CC+CG versus GG   CC versus CG+GG                                                                                    
  -------------- ---- ------------ -------------- -------------- ----------------- ----------------- ------- ------ ----------- ------- ------ ----------- ------- ------ ----------- -------
  Overall        10   1.32         1.03-1.71      0.032          1.34              0.69-2.61         0.388   1.50   1.03-2.19   0.033   1.44   1.05-1.99   0.026   1.15   0.57-2.34   0.696
  PCR-RFLP       7    1.52         1.15-2.02      0.004          1.50              0.71-3.16         0.287   1.84   1.19-2.86   0.007   1.74   1.20-2.51   0.003   1.26   0.56-2.83   0.572
  PCR            2    0.81         0.50-1.31      0.383          0.99              0.14-6.84         0.991   0.77   0.45-1.30   0.326   0.78   0.47-1.31   0.344   1.01   0.15-6.97   0.993
  Caucasian      5    1.13         0.89-1.43      0.316          0.80              0.21-3.02         0.740   1.26   0.70-2.29   0.445   1.20   0.77-1.87   0.417   0.72   0.16-3.31   0.675
  Asian          4    1.89         1.16-3.08      0.011          2.20              1.30-3.74         0.003   2.06   1.13-3.76   0.018   2.06   1.17-3.64   0.012   1.89   1.12-3.19   0.018
  Large sample   5    1.41         1.02-1.96      0.040          1.18              0.45-3.06         0.741   1.75   1.01-3.01   0.045   1.61   1.04-2.51   0.033   0.98   0.35-2.80   0.976
  Small sample   5    1.20         0.74-1.94      0.460          1.82              0.72-4.60         0.205   1.24   0.74-2.07   0.414   1.24   0.73-2.10   0.420   1.64   0.65-4.14   0.292
  HNC            7    1.15         0.93-1.43      0.188          0.92              0.32-2.67         0.883   1.26   0.81-1.96   0.301   1.22   0.87-1.71   0.255   0.81   0.25-2.62   0.729
  EC             3    2.07         1.01-4.25      0.048          2.08              1.17-3.71         0.013   2.38   0.96-5.89   0.060   2.31   1.00-5.35   0.050   1.78   1.00-3.15   0.049

###### 

Results of overall and subgroup analyses for rs1801321.

                 No   T versus G   TT versus GG   TG versus GG   TT+TG versus GG   TT versus TG+GG                                                                                    
  -------------- ---- ------------ -------------- -------------- ----------------- ----------------- ------- ------ ----------- ------- ------ ----------- ------- ------ ----------- -------
  Overall        4    1.11         0.66-1.87      0.686          1.12              0.37-3.40         0.846   1.17   0.78-1.76   0.451   1.16   0.67-2.03   0.592   1.05   0.40-2.76   0.926
  PCR-RFLP       2    1.46         0.48-4.48      0.504          3.02              0.12-76.6         0.502   1.42   0.64-3.17   0.394   1.52   0.50-4.65   0.463   2.56   0.15-44.5   0.518
  Caucasian      2    0.82         0.72-0.95      0.007          0.44              0.14-1.43         0.173   0.96   0.78-1.19   0.723   0.86   0.71-1.06   0.161   0.45   0.14-1.46   0.182
  Small sample   3    1.24         0.57-2.66      0.590          1.43              0.17-12.2         0.743   1.27   0.71-2.30   0.424   1.30   0.59-2.86   0.520   1.31   0.19-8.87   0.782

###### 

False-positive report probability values for the rs1801320 and rs1801321 gene polymorphisms.

  Variables         OR (95% CI)        *P* ^a^   Power^b^   Prior probability                           
  ----------------- ------------------ --------- ---------- ------------------- ------- ------- ------- -------
  rs1801320                                                                                             
  C versus G                                                                                            
  Overall           1.32 (1.03-1.71)   0.036     0.833      0.113               0.277   0.808   0.977   0.998
  PCR-RFLP          1.52 (1.15-2.02)   0.004     0.464      0.025               0.070   0.455   0.894   0.988
  Asian             1.89 (1.16-3.08)   0.011     0.177      0.153               0.351   0.856   0.984   0.998
  Large sample      1.41 (1.02-1.96)   0.041     0.644      0.160               0.364   0.863   0.984   0.998
  EC                2.07 (1.01-4.25)   0.047     0.190      0.428               0.692   0.961   0.996   1.000
  CC versus GG                                                                                          
  Asian             2.20 (1.30-3.74)   0.004     0.079      0.120               0.291   0.819   0.979   0.998
  EC                2.08 (1.17-3.71)   0.013     0.134      0.227               0.468   0.906   0.990   0.999
  CG versus GG                                                                                          
  Overall           1.50 (1.03-2.19)   0.036     0.500      0.177               0.391   0.876   0.986   0.999
  PCR-RFLP          1.84 (1.19-2.86)   0.007     0.182      0.100               0.250   0.786   0.974   0.997
  Asian             2.20 (1.30-3.74)   0.004     0.079      0.120               0.291   0.819   0.979   0.998
  Large sample      1.75 (1.01-3.01)   0.043     0.289      0.309               0.579   0.937   0.993   0.999
  CC+CG versus GG                                                                                       
  Overall           1.44 (1.05-1.99)   0.027     0.598      0.120               0.290   0.818   0.978   0.998
  PCR-RFLP          1.74 (1.20-2.51)   0.003     0.214      0.041               0.114   0.585   0.934   0.993
  Asian             2.06 (1.17-3.64)   0.013     0.137      0.219               0.457   0.902   0.989   0.999
  Large sample      1.61 (1.04-2.51)   0.036     0.377      0.220               0.459   0.903   0.989   0.999
  CC versus CG+GG                                                                                       
  Asian             1.89 (1.12-3.19)   0.017     0.193      0.210               0.444   0.898   0.989   0.999
  EC                1.78 (1.00-3.15)   0.048     0.278      0.340               0.607   0.944   0.994   0.999
  rs1801321                                                                                             
  T versus G                                                                                            
  Caucasian         0.82 (0.72-0.95)   0.008     0.997      0.024               0.069   0.449   0.892   0.988

^a^Chi-square test was adopted to calculate the genotype frequency distributions. ^b^Statistical power was calculated using the number of observations in the subgroup and the OR and *P* values in this table.

[^1]: Academic Editor: Byung-Hoon Jeong
